These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 17209570)
1. Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties. Jiang C; Chang JY Biochemistry; 2007 Jan; 46(2):602-9. PubMed ID: 17209570 [TBL] [Abstract][Full Text] [Related]
2. The role of the C-terminus of human α-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. Hong DP; Xiong W; Chang JY; Jiang C FEBS Lett; 2011 Feb; 585(3):561-6. PubMed ID: 21237164 [TBL] [Abstract][Full Text] [Related]
3. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Kumar S; Sarkar A; Sundar D Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781 [TBL] [Abstract][Full Text] [Related]
4. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. Brucale M; Sandal M; Di Maio S; Rampioni A; Tessari I; Tosatto L; Bisaglia M; Bubacco L; Samorì B Chembiochem; 2009 Jan; 10(1):176-83. PubMed ID: 19067456 [TBL] [Abstract][Full Text] [Related]
5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Conway KA; Harper JD; Lansbury PT Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558 [TBL] [Abstract][Full Text] [Related]
6. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease. Hong L; Simon JD J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659 [TBL] [Abstract][Full Text] [Related]
7. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Ramakrishnan M; Jensen PH; Marsh D Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533 [TBL] [Abstract][Full Text] [Related]
9. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H; Hasegawa T; Neumann M; Kahle PJ Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424 [TBL] [Abstract][Full Text] [Related]
10. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis. Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751 [TBL] [Abstract][Full Text] [Related]
11. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Bisaglia M; Tosatto L; Munari F; Tessari I; de Laureto PP; Mammi S; Bubacco L Biochem Biophys Res Commun; 2010 Apr; 394(2):424-8. PubMed ID: 20226175 [TBL] [Abstract][Full Text] [Related]
12. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Hoyer W; Cherny D; Subramaniam V; Jovin TM Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017 [TBL] [Abstract][Full Text] [Related]
13. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718 [TBL] [Abstract][Full Text] [Related]
14. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148 [TBL] [Abstract][Full Text] [Related]
15. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Li J; Uversky VN; Fink AL Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511 [TBL] [Abstract][Full Text] [Related]
16. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice. Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925 [TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Moussa CE; Wersinger C; Tomita Y; Sidhu A Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920 [TBL] [Abstract][Full Text] [Related]
18. A triple-emission fluorescent probe reveals distinctive amyloid fibrillar polymorphism of wild-type alpha-synuclein and its familial Parkinson's disease mutants. Celej MS; Caarls W; Demchenko AP; Jovin TM Biochemistry; 2009 Aug; 48(31):7465-72. PubMed ID: 19586054 [TBL] [Abstract][Full Text] [Related]
19. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052 [TBL] [Abstract][Full Text] [Related]
20. The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region. Meuvis J; Gerard M; Desender L; Baekelandt V; Engelborghs Y Biochemistry; 2010 Nov; 49(43):9345-52. PubMed ID: 20828147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]